- Home
- YALA vs NGNE Comparison
YALA vs NGNE Comparison
Compare YALA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | NGNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.1M | 744.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | YALA | NGNE |
|---|---|---|
| Price | $5.41 | $33.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | ★ 370.9K | 194.2K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.01 | $15.93 |
| 52 Week High | $8.10 | $43.66 |
Technical Indicators
Market Signals| Indicator | YALA | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 43.71 |
| Support Level | $5.20 | $31.20 |
| Resistance Level | $5.64 | $42.84 |
| Average True Range (ATR) | 0.09 | 2.43 |
| MACD | -0.01 | -0.42 |
| Stochastic Oscillator | 37.04 | 6.98 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.